Tryton Breakfast Symposium Session Introduction: The Challenge of Treating Bifurcation Lesions David G. Rizik, M.D., F.A.C.C., F.S.C.A.I. Chief Scientific Officer Director of Structural & Coronary Interventions HonorHealth and the Scottsdale - Lincoln HealthNetwork HonorHealth / Scottsdale - Lincoln Health Network
16
Embed
D.Rizik, tryton breakfast symposium introduction_the challenge of treating bifurcation lesions
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Scot
tsda
le-L
inco
ln H
ealth
Net
wor
k Tryton Breakfast SymposiumSession Introduction:
The Challenge of Treating Bifurcation Lesions
David G. Rizik, M.D., F.A.C.C., F.S.C.A.I.Chief Scientific Officer
Director of Structural & Coronary InterventionsHonorHealth and the Scottsdale-Lincoln
HealthNetworkHon
orH
ealth
/ Sco
ttsd
ale-
Lin
coln
Hea
lth N
etw
ork
Disclosure Statement of Financial Interest
I, (David G Rizik, MD), DO NOT have a financial interest/arrangement or
affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this
presentation
Scot
tsda
le-L
inco
ln H
ealth
Net
wor
kQ1: Why is stenting the standard for the
treatment of these lesions subsets?
• Discrete• Long Segmental• Calcified• Eccentric • Saphenous Vein Graphs• CTO’s• In-Stent Restenosis• Thrombotic• Type A, B1, B2, C
A1: Stenting provides a wide variety of lesion subsets predictable procedural
success with a durable result.
Scot
tsda
le-L
inco
ln H
ealth
Net
wor
kQ2: What is the only major lesion subset which
stenting is not the current Standard?
A2: Bifurcation Lesions: Workhorse stents do not provide the same predictable and durable results as straight lesion